MLND vs. ELDN, OCUP, CLRB, IMMP, ATAI, NKTR, VTYX, RZLT, ALDX, and ACRV
Should you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include Eledon Pharmaceuticals (ELDN), Ocuphire Pharma (OCUP), Cellectar Biosciences (CLRB), Immutep (IMMP), Atai Life Sciences (ATAI), Nektar Therapeutics (NKTR), Ventyx Biosciences (VTYX), Rezolute (RZLT), Aldeyra Therapeutics (ALDX), and Acrivon Therapeutics (ACRV). These companies are all part of the "medical" sector.
Eledon Pharmaceuticals (NASDAQ:ELDN) and Millendo Therapeutics (NASDAQ:MLND) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership, community ranking and risk.
Millendo Therapeutics' return on equity of -45.60% beat Eledon Pharmaceuticals' return on equity.
56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 11.7% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Eledon Pharmaceuticals currently has a consensus target price of $11.67, suggesting a potential upside of 306.50%. Given Millendo Therapeutics' higher probable upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Millendo Therapeutics.
Eledon Pharmaceuticals received 26 more outperform votes than Millendo Therapeutics when rated by MarketBeat users.
In the previous week, Eledon Pharmaceuticals had 8 more articles in the media than Millendo Therapeutics. MarketBeat recorded 8 mentions for Eledon Pharmaceuticals and 0 mentions for Millendo Therapeutics. Millendo Therapeutics' average media sentiment score of 0.94 beat Eledon Pharmaceuticals' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.
Eledon Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Millendo Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
Summary
Eledon Pharmaceuticals beats Millendo Therapeutics on 10 of the 11 factors compared between the two stocks.
Get Millendo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MLND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Millendo Therapeutics Competitors List
Related Companies and Tools
